Marc Voigt, Immutep CEO

Im­mutep picks up more funds for LAG-3 on­col­o­gy and au­toim­mune stud­ies

Im­mutep has raised about $53 mil­lion to bankroll its LAG-3 drugs across on­col­o­gy and au­toim­mune dis­eases, giv­ing it a cash run­way to the first quar­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.